Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 9/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.33 |
| ▸ | LTA4H | P09960 | 3/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4911008 | 0.82 | — | — | |
| SCHEMBL10523625 | 0.81 | NCF1 (0.35) | — | |
| SCHEMBL4924806 | 0.73 | CYP2D6 (0.46) | CYP2D6CYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11403001 | 0.71 | NR5A1 (0.40) | LTA4HTLR8NR5A1 | |
| SCHEMBL598441 | 0.69 | CYP2D6 (0.43) | CYP2D6CYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4915839 | 0.68 | CYP2D6 (0.41) | CYP2D6CYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4201803 | 0.67 | CYP2D6 (0.41) | CYP2D6CYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4723160 | 0.67 | DNM2 (0.36) | TLR8 | |
| SCHEMBL4268840 | 0.66 | CYP2D6 (0.48) | CYP2D6CYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5691816 | 0.66 | NR5A1 (0.33) | LTA4HTLR8NR5A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| EP-1866317-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103555-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PF4, TBXA2R, P2RY4 | CYP2D6 113/4885CYP3A4 325/4885CYP1A2 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.